Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT00281528

Public ClinicalTrials.gov record NCT00281528. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Weekly Versus Every 2-week Versus Every 3-week Administration of ABI-007 (Abraxane) in Combination With Bevacizumab in Women With Metastatic Breast Cancer.

Study identification

NCT ID
NCT00281528
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Celgene
Industry
Enrollment
208 participants

Conditions and interventions

Interventions

  • ABI-007 (Abraxane) Drug
  • bevacizumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2006
Primary completion
Jun 30, 2010
Completion
Feb 28, 2011
Last update posted
Nov 21, 2019

2006 – 2011

United States locations

U.S. sites
39
U.S. states
22
U.S. cities
35
Facility City State ZIP Site status
Division of Hematology/Oncology University of Alabama at Birmingham Birmingham Alabama
Little Rock Hematology Oncology Associates Little Rock Arkansas
California Oncology of the Central Valley Fresno California
Glendale Memorial Hospital & Health Center Glendale California
Front Range Cancer Specialists Fort Collins Colorado
Oncology Associates of Bridgeport Bridgeport Connecticut 06610
Palm Beach Institute of Hematology and Oncology Boynton Beach Florida
Memorial Cancer Institute/Breast Cancer Center Hollywood Florida 33021
Florida Cancer Institute Hudson Florida
Hematology Oncology Associates Lake Worth Florida
Medical Specialist of the Palm Beaches, Inc Lake Worth Florida
Gulfcoast Oncology Associates St. Petersburg Florida
Peachtree Hematology & Oncology Associates Atlanta Georgia
Northwest Georgia Oncology Centers, PC Marietta Georgia
Center of Hope for Cancers and Blood Stockbridge Georgia 30281
Maine Center for Cancer Medicine & Blood Disorders Scarborough Maine
Greater Baltimore Medical Center Baltimore Maryland
Harbor View Cancer Center Baltimore Maryland
Boston Medical Center Moakley Building, Solomont Center for Hematology & Medical Oncology Boston Massachusetts
North Shore Medical Cancer Center Peabody Massachusetts 01960
St. John's Mercy Medical Center St Louis Missouri
Nebraska Methodist Hospital Omaha Nebraska
Drs. Forte, Schleidere, & Attas, PA Englewood New Jersey
Saint Barnabas Medical Center Livingston New Jersey
Monmouth Medical Center Long Branch New Jersey
Rosewell Park Cancer Institute Elm & Carlton Carlton Building Buffalo New York
Beth Israel Comprehensive Cancer Center New York New York
Memorial Sloan Kettering Cancer Center New York New York
NYU Clinical Cancer Center New York New York
Marion L. Shepard Cancer Center Washington North Carolina
Medical Oncology Aultman Hospital Canton Ohio
Cancer Centers of Southwest Oklahoma Research Lawton Oklahoma
Abington Hematology Oncology Willow Grove Pennsylvania
Family Cancer Center Collierville Tennessee
Tennessee Cancer Specialists Knoxville Tennessee
TX Oncology, PA Austin Texas
South Texas Oncology & Hematology Clinical Research Dept. San Antonio Texas
Virginia Commonwealth University Medical Oncology Richmond Virginia
Swedish Cancer Institute Seattle Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00281528, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 21, 2019 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00281528 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →